ResearcherChina Pharmaceutical UniversityNo recent work listed

Xin Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8472-6498; OpenAlex author ID A5101916143. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper

Papers 1

Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. Co-author DOI 10.1016/j.carbpol.2019.115223 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Duiyue Xu · 1 shared paper, 2019 · strength 0.10
- Paper Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. DOI 10.1016/j.carbpol.2019.115223 ↗
Changlin Zhou · 1 shared paper, 2019 · strength 0.10
- Paper Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. DOI 10.1016/j.carbpol.2019.115223 ↗
Yiran Zhou · 1 shared paper, 2019 · strength 0.10
- Paper Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. DOI 10.1016/j.carbpol.2019.115223 ↗
Baiyong Shen · 1 shared paper, 2019 · strength 0.10
- Paper Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo. DOI 10.1016/j.carbpol.2019.115223 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.